This filing alone is not material. However, the broader pattern of elevated insider selling (9 transactions, $8.6M over 30 days) warrants monitoring for potential negative sentiment. Watch for any material adverse news or guidance changes in upcoming filings.
DYN drugs
DYN drug pipeline →- ▲ z-rostudirsen 8/10 Filed (BLA under FDA Priority Review); Phase 3 confirmatory trial (FORZETTO) ongoing · PDUFA date Jan 21, 2027
- ◆ z-basivarsen 7/10 Phase 3 (HARMONIA confirmatory trial, initiated March 2026); Phase 1/2 registrational cohort (ACHIEVE) fully enrolled · BLA filing Q3 2027
- ● DYNE-302 2/10
- All DYN drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 5 $17.47entry
- T+1 · 7mo ago +7.84%α +6.46% · $18.84
- T+5 · 6mo ago +5.15%α +3.17% · $18.37
- T+20 · 6mo ago −1.32%α −6.27% · $17.24
- T+60 · 4mo ago +47.28%α +44.54% · $25.73
Price Chart
How similar events traded
Executive Summary
Atlas Venture Opportunity Fund I, L.P., a major venture investor, filed a Form 144 indicating intent to sell 2,466 shares of Dyne Therapeutics, with an estimated value of approximately $42,884. The proposed sale is tiny relative to Dyne's $2.9B market cap and appears to be routine portfolio rebalancing. However, the filing comes amid a cluster of 9 insider sales totaling $8.6M over the past 30 days, which merits attention.
Key Facts
- Filing by Atlas Venture Opportunity Fund I, L.P., a VC fund, not an officer/director.
- Proposed sale of 2,466 shares of Dyna Therapeutics common stock.
- Estimated market value of ~$42,884 (based on current price).
- Filing date: 2026-05-04.
- Proposed sale represents ~0.0015% of market cap (negligible).
- Recent insider selling cluster: 9 sales totaling $8.6M in the last 30 days.
Financial Impact
Negligible; proposed sale value of ~$42,884 is minimal relative to ~$2.9B market cap.
Risk Factors
- Insider selling cluster may indicate negative outlook, but this specific filing is too small to be a signal.
- Venture fund sale could be routine liquidity event, not necessarily informed selling.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001628280-26-029910 |
| Document: 0001628280-26-029910-index.html | 0001628280-26-029910 |
| Document: 0001628280-26-029910.txt | 0001628280-26-029910 |
Track record
54 reports on DYN
12 of 16 bullish or bearish reports moved the stock their way by T+20. Best: +46.36% at T+60 after the May 20, 2026 report. 15 of 16 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $16.77 Now $16.70 −0.39% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $17.36 Now $16.70 −3.80% settles Dec 4
- Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $17.04 Now $16.70 −2.00% settles Nov 27
- Oct 22, 202625d ago Press Release Neutral 2/10 Entry $15.62 Now $16.70 +6.91% settles Nov 20
- Oct 12, 20265w ago Institutional Cluster Mixed 4/10 Entry $15.96 to $18.62 Now $16.70 +4.64% ▲ +16.67% +19.93% vs SPY
- Sep 29, 20266w ago Press Release Bullish 7/10 Entry $16.11 to $16.94 Now $16.70 +3.66% ▲ +5.15% +4.23% vs SPY
- Sep 8, 20269w ago Insider Cluster Neutral 3/10 Entry $19.19 to $15.97 Now $16.70 −12.98% ▼ −16.78% −18.72% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers